An observational study in Kidney Disease, Chronic and Heart Failure, sponsored by Pr. Semir Nouira. Completed. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-12.
Sponsored by Pr. Semir Nouira · Observational
the objective of this study is to :
-Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.
The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality.
Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho.
The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D.
But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.
subjects who visited the emmergency departement or the nephrology departement , meeting the criteria inclusion and have given a written consent .
Exclusion Criteria:
subjects with a Left Ventricular Ejection Fraction (LVEF) \<50% or LVEF \>50% and E/e'\>10.
subjects with LVEF\>50%
Fibroblast Growth Factor 23 (FGF23)
compare the circulating levels of FGF23 (pg/ml) in the two groups .
Time frame: completed data base (after 4 months)
Alpha Klotho
compare the circulating levels of klotho (ng/ml) in the two groups .
Time frame: completed data base (after 4 months)
No study locations are listed for this record.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pr. Semir Nouira